vs
Side-by-side financial comparison of Cullinan Therapeutics, Inc. (CGEM) and Roivant Sciences Ltd. (ROIV). Click either name above to swap in a different company.
Cullinan Therapeutics, Inc. produced more free cash flow last quarter ($-25.9M vs $-201.4M).
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel targeted oncology therapies to address unmet medical needs for patients with hard-to-treat cancers. Its core pipeline includes candidates for solid tumors and hematological malignancies, with operations and R&D partnerships spanning North America and global oncology research networks.
Roivant Sciences Ltd. is an American multinational healthcare company focused on applying technology to drug development and building subsidiary life sciences and health technology companies. It was founded in 2014 by Vivek Ramaswamy and is currently headed by CEO Matt Gline. Roivant maintains its headquarters in New York City as well as major offices in the biotech hubs of Boston and Basel.
CGEM vs ROIV — Head-to-Head
Income Statement — Q4 FY2022 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $0 | $2.0M |
| Net Profit | $-26.8M | $-265.9M |
| Gross Margin | — | — |
| Operating Margin | — | -16966.1% |
| Net Margin | — | -13301.2% |
| Revenue YoY | — | -77.8% |
| Net Profit YoY | 17.6% | -257.0% |
| EPS (diluted) | $-0.58 | $-0.38 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $2.0M | ||
| Q3 25 | — | $1.6M | ||
| Q2 25 | — | $2.2M | ||
| Q1 25 | — | $-39.6M | ||
| Q4 24 | — | $9.0M | ||
| Q3 24 | — | $4.5M | ||
| Q2 24 | — | $8.0M | ||
| Q1 24 | — | $28.9M |
| Q4 25 | — | $-265.9M | ||
| Q3 25 | — | $-113.5M | ||
| Q2 25 | — | $-223.4M | ||
| Q1 25 | — | $-206.5M | ||
| Q4 24 | — | $169.4M | ||
| Q3 24 | — | $-230.2M | ||
| Q2 24 | — | $95.3M | ||
| Q1 24 | — | $-151.1M |
| Q4 25 | — | -16966.1% | ||
| Q3 25 | — | -19492.9% | ||
| Q2 25 | — | -13130.0% | ||
| Q1 25 | — | 674.8% | ||
| Q4 24 | — | -3042.6% | ||
| Q3 24 | — | -7636.0% | ||
| Q2 24 | — | -1279.5% | ||
| Q1 24 | — | -919.5% |
| Q4 25 | — | -13301.2% | ||
| Q3 25 | — | -7225.9% | ||
| Q2 25 | — | -10292.9% | ||
| Q1 25 | — | 521.8% | ||
| Q4 24 | — | 1878.3% | ||
| Q3 24 | — | -5143.8% | ||
| Q2 24 | — | 1192.7% | ||
| Q1 24 | — | -522.3% |
| Q4 25 | — | $-0.38 | ||
| Q3 25 | — | $-0.17 | ||
| Q2 25 | — | $-0.33 | ||
| Q1 25 | — | $-0.28 | ||
| Q4 24 | — | $0.23 | ||
| Q3 24 | — | $-0.31 | ||
| Q2 24 | — | $0.12 | ||
| Q1 24 | — | $-0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $467.3M | $4.5B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $535.0M | $4.3B |
| Total Assets | $561.1M | $5.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $4.5B | ||
| Q3 25 | — | $4.4B | ||
| Q2 25 | — | $4.5B | ||
| Q1 25 | — | $4.9B | ||
| Q4 24 | — | $5.1B | ||
| Q3 24 | — | $5.4B | ||
| Q2 24 | — | $5.7B | ||
| Q1 24 | — | $6.5B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $311.7M | ||
| Q1 24 | — | $430.6M |
| Q4 25 | — | $4.3B | ||
| Q3 25 | — | $4.4B | ||
| Q2 25 | — | $4.3B | ||
| Q1 25 | — | $4.7B | ||
| Q4 24 | — | $5.2B | ||
| Q3 24 | — | $5.2B | ||
| Q2 24 | — | $5.4B | ||
| Q1 24 | — | $6.0B |
| Q4 25 | — | $5.2B | ||
| Q3 25 | — | $5.1B | ||
| Q2 25 | — | $5.0B | ||
| Q1 25 | — | $5.4B | ||
| Q4 24 | — | $5.8B | ||
| Q3 24 | — | $6.2B | ||
| Q2 24 | — | $6.5B | ||
| Q1 24 | — | $7.2B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.06× | ||
| Q1 24 | — | 0.07× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-25.0M | $-196.5M |
| Free Cash FlowOCF − Capex | $-25.9M | $-201.4M |
| FCF MarginFCF / Revenue | — | -10076.0% |
| Capex IntensityCapex / Revenue | — | 246.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-776.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-196.5M | ||
| Q3 25 | — | $-185.7M | ||
| Q2 25 | — | $-204.4M | ||
| Q1 25 | — | $-172.6M | ||
| Q4 24 | — | $-207.3M | ||
| Q3 24 | — | $-266.8M | ||
| Q2 24 | — | $-192.8M | ||
| Q1 24 | — | $-108.5M |
| Q4 25 | — | $-201.4M | ||
| Q3 25 | — | $-193.5M | ||
| Q2 25 | — | $-208.4M | ||
| Q1 25 | — | $-173.4M | ||
| Q4 24 | — | $-209.1M | ||
| Q3 24 | — | $-267.8M | ||
| Q2 24 | — | $-193.8M | ||
| Q1 24 | — | $-108.8M |
| Q4 25 | — | -10076.0% | ||
| Q3 25 | — | -12317.8% | ||
| Q2 25 | — | -9604.5% | ||
| Q1 25 | — | 438.1% | ||
| Q4 24 | — | -2318.5% | ||
| Q3 24 | — | -5984.4% | ||
| Q2 24 | — | -2425.5% | ||
| Q1 24 | — | -376.1% |
| Q4 25 | — | 246.9% | ||
| Q3 25 | — | 499.6% | ||
| Q2 25 | — | 185.9% | ||
| Q1 25 | — | -2.0% | ||
| Q4 24 | — | 20.3% | ||
| Q3 24 | — | 22.3% | ||
| Q2 24 | — | 12.1% | ||
| Q1 24 | — | 1.2% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -1.22× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -2.02× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
